资金流向方面，主力资金净流入146.07万元，特大单买入0.00元，占比0.00%，卖出104.81万元，占比 1.78%；大单买入1234.20万元，占比20.98%，卖出983.32万元，占比16.72%。 10月10日，金石亚药盘中上涨2.00%，截至14:27，报9.68元/股，成交5882.58万元，换手率1.79%，总市 值38.89亿元。 金石亚药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：医药电商、抗流感、中 药、零售药店、生物医药等。 截至6月30日，金石亚药股东户数2.28万，较上期增加14.00%；人均流通股15010股，较上期减少 12.28%。2025年1月-6月，金石亚药实现营业收入4.92亿元，同比减少5.80%；归母净利润6574.54万元， 同比增长67.71%。 分红方面，金石亚药A股上市后累计派现1.70亿元。近三年，累计派现7191.22万元。 责任编辑：小浪快报 金石亚药今年以来股价涨18.32%，近5个交易日涨0.73%，近20日跌3.49%，近60日跌3.39%。 今年以来金石亚药已经1次登上龙虎榜，最近一次登上龙虎榜为1月6日，当日龙虎榜净买 ...

10月10日，康弘药业盘中下跌2.02%，截至14:13，报35.92元/股，成交1.06亿元，换手率0.42%，总市值 330.94亿元。 资金流向方面，主力资金净流出117.29万元，特大单买入260.92万元，占比2.47%，卖出201.25万元，占 比1.90%；大单买入1200.69万元，占比11.36%，卖出1377.64万元，占比13.03%。 康弘药业今年以来股价涨89.05%，近5个交易日跌2.79%，近20日跌8.72%，近60日涨23.48%。 截至9月30日，康弘药业股东户数2.40万，较上期减少3.67%；人均流通股28624股，较上期增加3.81%。 2025年1月-6月，康弘药业实现营业收入24.54亿元，同比增长6.95%；归母净利润7.30亿元，同比增长 5.41%。 分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年6月30日，康弘药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2727.50万股，相比上期减少531.59万股。大成睿享混合A（008269）位居第六大流通股 东，持股1225. ...

10月9日，以岭药业盘中上涨2.01%，截至13:31，报16.21元/股，成交2.03亿元，换手率0.92%，总市值 270.82亿元。 以岭药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：创新药、抗癌药物、抗癌治 癌、中药、幽门螺杆概念等。 截至6月30日，以岭药业股东户数17.01万，较上期减少8.18%；人均流通股8093股，较上期增加8.91%。 2025年1月-6月，以岭药业实现营业收入40.40亿元，同比减少12.26%；归母净利润6.69亿元，同比增长 26.03%。 分红方面，以岭药业A股上市后累计派现39.54亿元。近三年，累计派现13.37亿元。 机构持仓方面，截止2025年6月30日，以岭药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股1759.21万股，相比上期减少567.82万股。南方中证500ETF（510500）位居第五大流通股 东，持股1239.65万股，相比上期增加176.50万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股384.98万股，相比上期减少43.25万股。 责任编辑：小浪快报 资金流向方面，主力资金净流入5 ...

资金流向方面，主力资金净流入1516.41万元，特大单买入1892.06万元，占比16.07%，卖出119.71万 元，占比1.02%；大单买入2560.02万元，占比21.75%，卖出2815.97万元，占比23.92%。 马应龙今年以来股价涨5.85%，近5个交易日涨0.37%，近20日涨1.24%，近60日涨0.33%。 资料显示，马应龙药业集团股份有限公司位于湖北省武汉市武昌南湖周家湾100号，成立日期1994年5月 9日，上市日期2004年5月17日，公司主营业务涉及药品制造、医药零售及批发以及医疗服务等。主营业 务收入构成为：治痔类45.53%，零售、批发34.93%，其他16.43%，医院诊疗3.11%。 马应龙所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：基因测序、医药电商、中药、 化妆品、民营医院等。 10月9日，马应龙盘中上涨2.00%，截至11:20，报26.98元/股，成交1.18亿元，换手率1.02%，总市值 116.30亿元。 截至6月30日，马应龙股东户数3.11万，较上期减少23.07%；人均流通股13825股，较上期增加29.98%。 2025年1月-6月，马应 ...

Core Viewpoint - Kanghong Pharmaceutical has shown significant stock performance with a year-to-date increase of 95.79%, despite a recent decline over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, up 5.41% year-on-year [2]. Stock Market Activity - As of September 30, the stock price of Kanghong Pharmaceutical was 37.20 yuan per share, with a market capitalization of 34.273 billion yuan. The stock experienced a trading volume of 163 million yuan and a turnover rate of 0.65% [1]. - The stock has seen a net outflow of 1.1269 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of September 19, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, with an average of 27,573 circulating shares per person, a decrease of 0.74% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed in the last three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].

资料显示，健康元药业集团股份有限公司位于广东省深圳市南山区高新区北区朗山路17号健康元药业集 团大厦，成立日期1992年12月18日，上市日期2001年6月8日，公司主营业务涉及公司属于综合性制药企 业,主要从事中药、保健品及西药的研究、开发及生产经营。主营业务收入构成为：化学制剂47.71%， 化学原料药及中间体31.97%，中药制剂10.28%，诊断试剂及设备4.74%，保健食品3.08%，生物制品 1.20%，其他(补充)0.86%，其他0.15%。 健康元所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、AI医药、原料 药、中药、辅助生殖等。 截至6月30日，健康元股东户数7.63万，较上期减少4.32%；人均流通股23991股，较上期增加4.52%。 2025年1月-6月，健康元实现营业收入78.98亿元，同比减少4.08%；归母净利润7.85亿元，同比增长 1.10%。 分红方面，健康元A股上市后累计派现39.79亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年6月30日，健康元十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股6837.85万 ...

Core Viewpoint - Fangsheng Pharmaceutical has shown a positive stock performance with a year-to-date increase of 20.68% and a recent surge of 12.06% over the past five trading days, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2]. - The top ten circulating shareholders include notable institutional investors, with ICBC Medical Health Stock holding 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed Fund increasing its holdings by 500,000 shares to 5 million [3]. Market Activity - On September 26, Fangsheng Pharmaceutical's stock price rose by 2.11% to 12.08 yuan per share, with a trading volume of 125 million yuan and a turnover rate of 2.42%, resulting in a total market capitalization of 5.304 billion yuan [1]. - The net inflow of main funds was 4.67 million yuan, with significant buying activity from large orders, indicating strong investor interest [1].

Company Overview - JiuZhiTang has seen a stock price increase of 32.19% year-to-date, but has experienced a slight decline of 0.30% over the last 5 trading days and a more significant drop of 11.53% over the last 20 days [2] - The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs, with its main revenue sources being prescription drugs (50.27%) and OTC products (46.11%) [2] Financial Performance - For the first half of 2025, JiuZhiTang reported a revenue of 1.265 billion yuan, representing a year-on-year decrease of 24.71%, while the net profit attributable to shareholders was 144 million yuan, down 29.71% year-on-year [3] - Cumulative cash dividends since the company's A-share listing amount to 4.364 billion yuan, with 935 million yuan distributed over the past three years [4] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 50,500, marking a 25.14% rise, while the average number of circulating shares per person decreased by 20.09% to 13,739 shares [3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [4] Market Activity - On September 26, JiuZhiTang's stock rose by 2.12%, reaching 10.13 yuan per share, with a trading volume of 1.11 billion yuan and a turnover rate of 1.62% [1] - The net inflow of main funds was 593,400 yuan, with significant buying and selling activity recorded [1]

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. The company was listed on November 16, 2017. Its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1][2]. Financial Performance - As of August 31, Yipinhong reported a revenue of 584 million yuan for the first half of 2025, a year-on-year decrease of 36.02%. The net profit attributable to shareholders was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has cumulatively distributed 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yipinhong's stock price decreased by 2.00%, trading at 58.30 yuan per share, with a total market capitalization of 26.334 billion yuan. The stock has increased by 241.74% year-to-date but has seen a decline of 4.06% in the last five trading days and 11.84% in the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a stock trading list) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period. The average circulating shares per person decreased by 0.49% to 19,553 shares [2]. - As of June 30, 2025, the eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]. Industry Classification - Yipinhong belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with concepts including anti-influenza, pharmaceutical e-commerce, hepatitis treatment, monkeypox concept, and traditional Chinese medicine [2].